GE HealthCare's new logoGE HealthCare

(Nasdaq: GEHC)

today announced the launch of its “new era” of AI-enhanced oncology solutions, known as Revolution RT.

Revolution RT is a new radiation therapy computed tomography (CT) solution with innovative hardware and software solutions to increase imaging accuracy and simplify simulation workflow. The Chicago-based company designed the technology to create a more personalized and seamless oncology care pathway experience for clinicians and patients. The technology was showcased at the European Society for Therapeutic Radiology and Oncology 2024 Congress in Glasgow, Scotland.

The company also launched an updated and artificial intelligence (AI)-enhanced version of the Intelligent Radiation Therapy Platform (iRT) that interfaces with the Spectronic magnetic resonance imaging Planner.

“At GE HealthCare, we are committed to advancing the frontiers of oncology treatment through AI-driven technologies that transform and optimize the care continuum,” Chief Technology and Science Officer Taha Kass-Hout said in a news release.

According to the company, one of the biggest challenges of oncology care is the complexity of the disease. It presents itself in many different ways in individual patients, requiring diligence and personalization in diagnosis and treatment. However, treatment often requires the expertise of multiple disciplines and experts related to specific organs and systems in the body, which can lead to delays in diagnosis and treatment.

“Our showcase at ESTRO this year highlights innovations that will allow clinicians to view the patient’s anatomy with great accuracy, helping facilitate precise tumor targeting while aiming to protect nearby healthy tissue. By integrating these capabilities into our systems, we create a precise, more connected, and efficient care environment that accelerates the delivery of personalized and timely care, with the goal of enabling better patient outcomes. This comprehensive approach empowers clinicians around the globe to tackle the most challenging disease states with precision and efficiency,” Kass-Hout said.